Matt O'Brien
Stock Analyst at Piper Sandler
(2.24)
# 2,632
Out of 4,877 analysts
179
Total ratings
43.24%
Success rate
-5.24%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $132.06 | +9.80% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $60.67 | +31.86% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $6.01 | +99.83% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $21.98 | +36.52% | 2 | May 8, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $90 | $83.78 | +7.42% | 11 | May 2, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $11.14 | +34.65% | 3 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $36 → $30 | $17.87 | +67.88% | 8 | May 1, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $101.95 | +61.84% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $16.19 | +66.82% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $1.95 | +2.56% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $4.22 | -17.06% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.85 | +13.96% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $13.49 | +92.74% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $299.00 | +3.68% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $249.93 | +32.04% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $32.55 | +53.61% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $17.18 | -6.84% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $104.35 | +10.21% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.45 | +120.18% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $396.42 | +5.95% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $122.42 | +14.37% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $58.08 | +29.13% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $88.34 | +1.88% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $55.01 | +45.43% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $18.76 | +33.26% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.39 | +25.52% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.20 | +104.55% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $94.35 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.82 | +431.91% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $73.42 | +48.12% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.63 | +591.25% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $31.61 | +153.08% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.54 | +238.98% | 1 | Jun 24, 2020 |
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $132.06
Upside: +9.80%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $60.67
Upside: +31.86%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $6.01
Upside: +99.83%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $21.98
Upside: +36.52%
DexCom
May 2, 2025
Maintains: Overweight
Price Target: $100 → $90
Current: $83.78
Upside: +7.42%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $11.14
Upside: +34.65%
Tandem Diabetes Care
May 1, 2025
Maintains: Overweight
Price Target: $36 → $30
Current: $17.87
Upside: +67.88%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $101.95
Upside: +61.84%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $16.19
Upside: +66.82%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.95
Upside: +2.56%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $4.22
Upside: -17.06%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.85
Upside: +13.96%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $13.49
Upside: +92.74%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $299.00
Upside: +3.68%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $249.93
Upside: +32.04%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $32.55
Upside: +53.61%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $17.18
Upside: -6.84%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $104.35
Upside: +10.21%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.45
Upside: +120.18%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $396.42
Upside: +5.95%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $122.42
Upside: +14.37%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $58.08
Upside: +29.13%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $88.34
Upside: +1.88%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $55.01
Upside: +45.43%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $18.76
Upside: +33.26%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.39
Upside: +25.52%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.20
Upside: +104.55%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $94.35
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.82
Upside: +431.91%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $73.42
Upside: +48.12%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.63
Upside: +591.25%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $31.61
Upside: +153.08%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.54
Upside: +238.98%